Second Remission in Relapsed Childhood Acute Myelogenous Leukemia After Pretreatment with the AML-BFM 83 Protocol

  • K. Stahnke
  • U. Creutzig
  • J. Ritter
  • AML-BFM Study Group
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

In Germany more than 80% of newly diagnosed children with acute myelogenous leukemia are treated within the cooperative Berlin-Frankfurt-Münster (BFM) studies. Complete remissions (CR) of 80% are achieved with these protocols but one-third of patients relapse within the first 3 years [1]. There are only a few studies on the treatment of relapsed childhood AML; these aim at evaluating new antileukemic drugs for frontline therapy. Most of the studies enrolled either patients with relapsed AML or patients with leukemia refractory to frontline treatment. With various therapeutic regimens complete remission rates of 45%–49% were achieved [2–5]. Except for patients with allogenic bone marrow transplantation, reports on long-time survival are lacking.

Keywords

Leukemia Oncol Prednisolone Etoposide Cytosine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75: 1932–1940PubMedGoogle Scholar
  2. 2.
    Mirro J, Crom WR, Kalwinsky DK, Santane VM, Baker DK, Belt J (1990) Targeted plasma drug concentration: a new therapeutic approach to relapsed nonlymphoblastic leukemia in children. Hematology and Blood Transfusion 32: 82–86Google Scholar
  3. 3.
    Movassaghi N, Higgins G, Pyesmany A, Baehner R, Chard R, Sather H, Hammond D (1984) Evaluation of Cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with Cytosine Arabinoside: A Report from Children’s Cancer Study Group. Medical and Pediatric Oncology 12: 352–356PubMedCrossRefGoogle Scholar
  4. 4.
    Miller LP, Pyesmany AF, Wolff LJ, Rogers PCJ, Siegel SE, Wells RJ, Buckley JD, Hammond GD (1991) Successful reinduction therapy with Amsacrine and Cyclocytidine in acute nonlymphoblastic leukemia in children. Cancer 67: 2235–2240PubMedCrossRefGoogle Scholar
  5. 5.
    Hakami N, Look AT, Steuber PC, Krischer J, Castleberry R, Harris R, Ravindranath Y, Yietti TJ (1987) Combined Etoposide and 5-Azacitidine in children and adolescents with refractory or relapsed acute non lymphocytic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 5: 1022–1025PubMedGoogle Scholar
  6. 6.
    Ritter J, Creutzig U, Henze G, Jürgens H, Bode U, Prindull G, Schellong G (1987) Hochdosiertes ARA-C in Kombination mit Mitoxantron bei der Therapie der AML in Kindesalter. Erste Ergebnisse der AML-Rezidivstudie BFM-85. Onkologie 10: 24–27PubMedCrossRefGoogle Scholar
  7. 7.
    Kantarjian HM, Keating MJ, Walters RS, CrCredie KB, Freireich EJ (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. Journal of Clinical Oncology 6(2): 232–238PubMedGoogle Scholar
  8. 8.
    Hiddemann W, Martin W-R, Sauerland C-M, Heinecke A, Büchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid Leukemia: A proposal based on the results of retreatment by Thioguanine, Cytosine, Arabinoside and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line Therapy Leukemia 4(3): 184–188Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • K. Stahnke
    • 1
  • U. Creutzig
    • 2
  • J. Ritter
    • 2
  • AML-BFM Study Group
  1. 1.Abteilung Kinderheilkunde IIUniversitäts-Kinderklinik UlmUlmGermany
  2. 2.Universitäts-Kinderklinik MünsterMünsterGermany

Personalised recommendations